• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aligos Therapeutics Inc (NQ: ALGS )

    9.780 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Aligos Therapeutics Inc

    < Previous 1 2 3 Next >
    Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
    Three abstracts accepted for poster presentations on ALG-000184 and ALG-055009 
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Appoints David Perry as Vice President of Business Development
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Present at Investor Conferences in October
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces Reverse Stock Split
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Strengthens Board with Two New Independent Directors
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.